Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions International, Inc. (TSOI) generates a steady flow of news centered on immune modulation, stem cell therapy, immunotherapy, and nutraceutical development. This news page aggregates company announcements so readers can follow how its clinical-stage programs, patents, and subsidiaries evolve over time.
Recent press releases highlight progress with the company’s JadiCell universal donor stem cell product in areas such as lung inflammation, COVID-19–related conditions, ARDS, epilepsy, and ALS. News items also cover mechanistic discoveries about how JadiCells interact with immune cells, as well as data suggesting that these cells may enhance gene therapy–mediated production of therapeutic cells.
Another major stream of updates involves the nutraceutical QuadraMune. The company has announced multiple patents related to QuadraMune’s effects on immune pathways, including natural killer cell activity, viral inhibition, brain protection, and modulation of regulatory T cells. These developments are reflected in patent-related news and scientific commentary from company representatives.
Therapeutic Solutions International also issues news about its subsidiaries and pre–spin-off entities, such as Campbell Neurosciences in suicide prevention, Res Nova Bio in oncology immunotherapy, Epilepsy Bio in epilepsy, and ALS Biologics in ALS. Announcements may describe clinical observations under Right To Try, plans for public listings, loyalty dividends of subsidiary shares, and strategic positioning of intellectual property.
In addition, the company has released statements on legal actions and corporate decisions, including its plan to voluntarily delist and "go dark" from the public markets. Investors and observers can use this news feed to review historical announcements on clinical progress, patents, subsidiary formation, legal matters, and capital markets strategy related to TSOI.
Therapeutic Solutions International announced advancements in its COPD program alongside a pivotal COVID-19 clinical trial. New data reveals that combining JadiCell™ with Myeloid Derived Suppressor Cells enhances therapeutic efficacy, reducing lung damage and encouraging pulmonary regeneration. The FDA-cleared drug Leukine was also shown to boost Myeloid Derived Suppressor cell levels, improving JadiCell activity. The company has filed an Investigational New Drug application for JadiCells in COPD treatment and is exploring collaborations with immunotherapy stakeholders.
Therapeutic Solutions International has filed an Investigational New Drug (IND) application with the FDA to treat 10 patients with advanced COPD using its stem cell product, JadiCell™. The company is also developing JadiCell for COVID-19 and Chronic Traumatic Encephalopathy (CTE). Previous studies indicate JadiCell's effectiveness, including a 100% survival rate in COVID-19 patients under 85. The CEO expressed gratitude for the scientific team's efforts leading to this clinical trial application, marking a significant milestone in the company's research and development efforts.
Therapeutic Solutions International has launched a landmark double-blind clinical trial for its JadiCell™ therapy targeting COVID-19 associated lung failure, involving 128 patients across multiple nations. The primary goal is to assess the survival rate and respiratory health of patients at Day 60 post-treatment. The company holds the issued patent for JadiCell and has completed prior trials with a 100% survival rate in patients under 85. The collaboration with Biorasi aims for rapid patient recruitment to expedite FDA marketing approval.
Therapeutic Solutions International announced significant advancements in their JadiCell™ adult stem cell product, which promotes the regeneration of lung tissue. Recent experiments in mice show that intravenous JadiCells preserve lung function and stimulate lung repair cells, offering hope for chronic conditions like Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). The company is preparing to initiate a Phase III clinical trial for COVID-19-related lung failure, aiming to further validate the therapeutic potential of JadiCells.
Therapeutic Solutions International (TSOI) clarified a previous statement regarding the Principal Investigator for its clinical trial. Dr. James Veltmeyer has been appointed as the Principal Investigator pending FDA approval of TSOI as the trial's sponsor. Additionally, TSOI clarified that JadiCell adult stem cells are derived from umbilical cords and classified as mesenchymal-like stromal cells. The company focuses on immune modulation treatments for various diseases, with a commitment to advancing their clinical research.
Therapeutic Solutions International (TSOI) has appointed Biorasi as the contract research organization to conduct its Pivotal FDA Registration Clinical Trial for the JadiCell™ Adult Stem Cell Product, aimed at treating advanced COVID-19. The trial is a continuation of previous research that achieved a 100% survival rate in patients under 85. JadiCells™ show promising therapeutic activity for lung conditions. The trial will expand internationally, with India and another Latin American country involved, furthering TSOI's pursuit to be the first to market stem cell treatments for lung regeneration.
Therapeutic Solutions International (TSOI) has executed a purchase agreement for sponsorship of a pivotal Phase III clinical trial evaluating JadiCell adult stem cells for treating COVID-19 related lung failure.
Dr. Thomas Ichim emphasized the trial's impact on both COVID-19 and ARDS patients, with potential FDA registration for JadiCell as a leading cell-based therapy. The company has secured multiple patents for JadiCell, enhancing its market position. Dr. James Veltmeyer is designated as the Principal Investigator, taking control of trial conduct. TSOI acknowledges shareholder support during this significant initiative.
Therapeutic Solutions International announced the issuance of U.S. Patent #11,266,707 for its nutraceutical QuadraMune®, aimed at preventing and treating COVID-19. This patent complements a previous one covering its mechanism of action against indolamine 2,3 deoxygenase. Additionally, patent applications related to neuroprotection and neuroregeneration have been published. Company leaders emphasize the significance of these patents in validating their scientific approach to immune modulation and dual therapy strategies against COVID-19.
Therapeutic Solutions International announced a novel procedure, ApoptoCyte, enhancing the anti-inflammatory effects of mesenchymal stem cells. Data from a patent application indicates that combining apoptotic bodies with FDA-approved agents demonstrates superior therapeutic activity in animal models compared to traditional methods. This method potentially simplifies FDA approval processes due to minimal manipulation of stem cells. The company has cleared a Phase III trial for its JadiCell product in lung failure due to COVID-19, showing promising results over other stem cells.
Therapeutic Solutions International announced positive preclinical efficacy and safety data for its CampbellCell™ allogeneic primed mesenchymal stem cell therapy, targeting schizophrenia. The company previously filed a substantial patent covering stem cell approaches for treating schizophrenia in September 2020. Collaborations with Campbell Neurosciences have led to significant advancements, including recruiting industry experts and establishing a blood-based marker for suicidal tendencies. The development may represent a breakthrough in treating mental health disorders that often rely on invasive methods.